i. Audited Financial Results of the Company for the Half Yearly and Financial year ended March 31, 2025. ii. Adoption Related Party Transcation Policy as per Regulation 23 of SEBI (Listing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Amwill Health Care Ltd met on May 29, 2025 and approved audited financial results for the half-year and full year ended March 31, 2025. Revenue from operations for FY25 stood at about ₹43.94 crore versus ₹41.29 crore in FY24, with profit after tax rising to roughly ₹4.74 crore from about ₹3.16 crore, an increase of around 50%. The statutory auditor M/s SKLR & Co. LLP issued an unmodified (clean) opinion on the results. The Board also approved an amendment to the Related Party Transaction Policy in line with SEBI's March 2025 changes to Regulation 23, and cleared a ₹10 crore investment in AAA+ rated mutual funds via Kotak Mahindra using surplus cash. The company recently listed on the BSE SME platform in February 2025 after raising ₹48.88 crore through its IPO.
Strong profit growth (~50% YoY) with a clean audit opinion is a positive signal for shareholders, though the stock trades on the SME platform with limited liquidity. The ₹10 crore mutual fund deployment signals surplus cash but may draw scrutiny given it represents a meaningful portion of the company's recent IPO proceeds.